Showing results (171-180 of 204) with videos related to
Sort By:
Pageof 21
Nature Biotechnology|January 22, 2003
Flow-cytometric isolation of human antibodies from a nonimmune Saccharomyces cerevisiae surface display libraryMichael J Feldhaus, Robert W Siegel, Lee K Opresko, et al.Journal of Medicinal Chemistry|January 24, 2003
Indanylidenes. 1. Design and synthesis of (E)-2-(4,6-difluoro-1-indanylidene)acetamide, a potent, centrally acting muscle relaxant with antiinflammatory and analgesic activityDavid L Musso, Felicia R Cochran, James L Kelley, et al.Breast Cancer Research : BCR|February 24, 2026
Outcomes of once daily and twice daily accelerated partial breast irradiation regimens in hormone receptor positive breast cancer: a single institution experienceTanun Jitwatcharakomol, Yevgeniya Gokun, Sierra J Daniel, et al.Oncoimmunology|December 7, 2017
CAR T-cell immunotherapy of MET-expressing malignant mesotheliomaThivyan Thayaparan, Roseanna M Petrovic, Daniela Y Achkova, et al.Cancer Immunology, Immunotherapy : CII|September 16, 2008
NK1.1+ cells mediate the antitumor effects of a dual Toll-like receptor 7/8 agonist in the disseminated B16-F10 melanoma modelCalin D Dumitru, Mary A Antonysamy, Kevin S Gorski, et al.Biomaterials|February 10, 2015
Delivery of an engineered HGF fragment in an extracellular matrix-derived hydrogel prevents negative LV remodeling post-myocardial infarctionSonya B Sonnenberg, Aboli A Rane, Cassie J Liu, et al.Proceedings of the National Academy of Sciences of the United States of America|March 14, 2024
Structural insights reveal interplay between LAG-3 homodimerization, ligand binding, and functionJohn L Silberstein, Jasper Du, Kun-Wei Chan, et al.Nature Medicine|November 9, 2019
Antitumor activity of an engineered decoy receptor targeting CLCF1-CNTFR signaling in lung adenocarcinomaJun W Kim, Cesar P Marquez, Kaja Kostyrko, et al.The Journal of Cell Biology|March 29, 2018
TRRAP is a central regulator of human multiciliated cell formationZhao Wang, Lindsey W Plasschaert, Shivani Aryal, et al.The Journal of Experimental Medicine|May 6, 2017
Integrin-targeted cancer immunotherapy elicits protective adaptive immune responsesByron H Kwan, Eric F Zhu, Alice Tzeng, et al.Pageof 21